Publications by authors named "Kamyar Afshar"

BACKGROUND Acute respiratory distress syndrome (ARDS) due to coronavirus 2019 (COVID-19) can result in severe disease requiring mechanical ventilatory support. A subset of these patients, however, demonstrate refractory hypoxemia/hypercarbia requiring veno-venous extracorporeal membrane oxygenation (V-V ECMO) as adjunctive therapy. The primary goal of V-V ECMO is a "bridge" to recovery of native lung function; however, patients may progress to irreversible pulmonary damage requiring lung transplantation.

View Article and Find Full Text PDF
Article Synopsis
  • * Recent research indicates that IPF develops when alveolar epithelial type II (AT2) cells change and lose their ability to repair lung tissue due to abnormal differentiation, but the reasons behind this change are not fully understood.
  • * An analysis of AT2 cells in IPF patients revealed significant changes, particularly an enhancer activation in the TRIP13 gene, and using a TRIP13 inhibitor in lab settings showed promise in preventing the harmful differentiation associated with IPF, suggesting a new potential therapy.
View Article and Find Full Text PDF
Article Synopsis
  • Mitochondrial deficiencies in mouse airway tissues were investigated by inactivating the Lonp1 gene, showing varied effects on progenitor cells and ciliated cells during both development and disease.
  • Mitochondrial dysfunction resulted in issues like reduced progenitor cell growth, ciliated cell death, and issues with progenitor migration after influenza infection, linked to increased ATF4 and the integrated stress response.
  • The study suggests that lower LONP1 levels may contribute to the development of chronic obstructive pulmonary disease (COPD) and influence cell behavior through a changed energy environment, potentially leading to harmful cell types.
View Article and Find Full Text PDF

Background: There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF) in clinic. radix (AR; Huangqi) and radix (AS; Danggui) have been frequently used in the treatment of IPF. This study aimed to reveal the pharmacological effects and the mechanisms of the action of an AR-AS combination in treating IPF.

View Article and Find Full Text PDF
Article Synopsis
  • National data shows an increasing use of hepatitis C virus (HCV)-infected organ donors for lung transplants in the US, prompting a study on rejection rates between HCV-viremic and uninfected donors.
  • The study reviewed 135 lung transplant patients, finding that those receiving organs from HCV-viremic donors developed acute HCV infections but were successfully treated without serious complications.
  • Results indicated that HCV-viremic donors had lower rates of significant rejection (5.9%) compared to HCV-negative donors (11%), with 100% one-year survival in the former group versus 95.8% in the latter.
View Article and Find Full Text PDF

The triazole antifungal isavuconazole (ISAVU) is used for prevention and treatment of fungal infections in solid organ transplant (SOT). SOT recipients commonly need to transition from one azole to another due to breakthrough infection, toxicity, or other reasons. The purpose of our study was to evaluate the effect of ISAVU on immunosuppressant concentrations in thoracic transplant recipients when ISAVU was started de novo or transitioned from another azole.

View Article and Find Full Text PDF

Limited data is available for American Indians/Alaska Natives (AI/AN) undergoing lung transplant. The goal of our study was to assess outcomes for AI/AN lung transplant recipients (LTR). A retrospective review of data from the Organ Procurement and Transplant Network was performed comparing AI/AN (n = 88) and Caucasian (n = 22,767) LTRs between May 4, 2005 and October 31, 2019.

View Article and Find Full Text PDF

Background: After lung transplant, 2 common complications are calcineurin inhibitor (CNI) induced nephrotoxicity and bronchiolitis obliterans syndrome. The objective of this study was to investigate the long-term effects of sirolimus conversion after lung transplantation.

Methods: This was a retrospective cohort study of patients who had undergone lung transplantation at a single center from June 2003 to December 2016.

View Article and Find Full Text PDF

A 54-year-old woman with systemic lupus erythematosus with associated interstitial lung disease (ILD) presented to the lung transplant clinic for assessment of candidacy for transplantation. She was initially diagnosed with ILD based on clinical and radiographic features (never underwent lung biopsy). In addition, she had associated mixed group I/III pulmonary arterial hypertension.

View Article and Find Full Text PDF

A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

View Article and Find Full Text PDF

We present a case of end-stage lung disease secondary to mixed connective tissue disease (MCTD) with concomitant myocarditis found on explant at time of transplant. The patient is a 37-year-old man who was first diagnosed with interstitial lung disease secondary to MCTD at 30 years of age. He underwent en bloc heart-lung transplant for progressive decline in left ventricular ejection fraction and severe pulmonary fibrosis despite immunosuppression with hydroxychloroquine, mycophenolate, and azathioprine.

View Article and Find Full Text PDF

Bacteriophage therapy is the use of viruses to kill bacteria for the treatment of antibiotic-resistant infections. Little is known about the human immune response following phage therapy. We report the development of phage-specific CD4 T cells alongside rising phage-specific immunoglobulin G and neutralizing antibodies in response to adjunctive bacteriophage therapy used to treat a multidrug-resistant Pseudomonas aeruginosa pneumonia in a lung transplant recipient.

View Article and Find Full Text PDF

Goals: We aimed to evaluate a novel upper esophageal sphincter (UES) assist device loaner program for the prevention of acute cellular rejection and chronic lung allograft dysfunction among lung transplant (LTx) recipients.

Background: Laryngopharyngeal reflux can lead to chronic microaspiration and LTx rejection. The UES assist device applies external pressure at the level of UES to decrease reflux.

View Article and Find Full Text PDF

This article is co-authored by a patient living with alpha-1 antitrypsin deficiency, and her treating physician. The commentary article describes the patient's experience of the diagnosis and treatment process. The physician then discusses alpha-1 antitrypsin deficiency diagnosis and management in the context of the patient's experiences.

View Article and Find Full Text PDF

Patients with idiopathic pulmonary arterial hypertension (IPAH) have improved survival after heart-lung transplantation (HLT) and double-lung transplantation (DLT). However, the optimal procedure for patients with IPAH undergoing transplantation remains unclear. We hypothesized that critically ill IPAH patients, defined by admission to the intensive care units (ICU), would demonstrate improved survival with HLT vs.

View Article and Find Full Text PDF

Purpose Of Review: Immunosuppression regimens have helped improve rejection episodes following lung transplantation, but long-term outcomes are still not comparable with cardiac, hepatic, or renal transplantation. This review summarizes the immunobiology that contributes to rejection events and future opportunities in outcomes on the basis of providing optimized delivery of the immunosuppression based on immune-monitoring techniques, taking into account individual patient pharmacokinetics and phenotypic variance.

Recent Findings: Drug toxicities, narrow therapeutic drug monitoring windows, and current immunoassays currently do not assist in detecting the global degree of immunosuppression.

View Article and Find Full Text PDF

Background: Lung transplant recipients are at great risk for developing various infectious complications. These infections portend a significant morbidity and mortality throughout their lifetime following transplantation. At times, cutaneous manifestations are the only clues to systemic infection.

View Article and Find Full Text PDF

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation with an annual incidence rate of 3-5% in lung-transplant recipients. Pathogenesis indicates a strong association with functional over-immunosuppression and EBV infection. Clinical improvement is generally observed with reduction in immunosuppression intensity alone.

View Article and Find Full Text PDF

Pericardial constriction is extremely rare after lung transplantation. We present a case and review the potential contributing factors for pericardial constriction after lung transplantation. Treatment for this condition, irrespective of the cause, remains pericardiectomy.

View Article and Find Full Text PDF
Article Synopsis
  • - Sarcoidosis primarily affects the lungs, but can involve any organ, with rare gastrointestinal involvement, typically affecting the stomach.
  • - Symptoms of gastrointestinal sarcoidosis can vary, including epigastric pain, nausea, vomiting, and sometimes hematemesis, with some patients experiencing no noticeable symptoms.
  • - The study presents two cases of gastric sarcoidosis and analyzes 44 reported cases, highlighting the importance of recognizing its clinical manifestations and endoscopic findings.
View Article and Find Full Text PDF

Introduction: Community-acquired pneumonia is the most common manifestation in primary coccidioides infections (Coccidioides immitis, C. posadasii). It is essential that this endemic dimorphic fungus be considered in order to proceed with the most appropriate diagnostic tools and therapy.

View Article and Find Full Text PDF

Purpose Of Review: To examine recent reports of serosal involvement in sarcoidosis.

Recent Findings: Peritoneal sarcoidosis continues to be a rare manifestation of the disease. Patients with peritoneal disease tend to be women between the ages of 20 and 40 years, and most commonly present with ascites and abdominal pain.

View Article and Find Full Text PDF